The first case of e-cigarette, or vaping, associated lung injury (EVALI) diagnosed and treated in Europe reminds us to remain vigilant for this diagnosis, and importantly, that we are still learning about the full spectrum of risks of e-cigarette use
are based on a working case definition and remain quite broad diagnostically. In fact, many of the pulmonary diseases previously reported to be caused by e-cigarette use outside of this outbreak [2] , such as acute hypersensitivity pneumonitis, acute eosinophilic pneumonia, acute respiratory distress syndrome and others, meet this case definition. Indeed, it remains unclear whether even the current outbreak of EVALI has only a single cause. This case is important for two major reasons: first, it reminds us all that "no man is an island" [9] , no man ever was, though especially in our modern global society where, through the movement of people and goods (e-cigarettes), we are more interconnected than ever. EVALI, while reported predominantly in the USA, is of concern to people who vape and their clinicians across the world.
Second, while (hopefully) we may be starting to see the waning of this specific outbreak of EVALI [1] , it serves as a reminder that the risks associated with vaping and e-cigarette use are incompletely understood and evolving. Given the diversity of products and devices, and how people use them, it will be important to remain attentive, not only for diagnosing EVALI in the context of this outbreak, but for future possible outbreaks as use patterns and products change.
While Europeans seem to have escaped the scourge of "homegrown" EVALI for now, given the rapidly increasing popularity of e-cigarettes around the world [10] , we must remain vigilant not only to new vaping-associated illnesses, but also to the rising rate of e-cigarette use among children [11] .
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